Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.

International journal of radiation oncology, biology, physics - 1 Dec 2013

Fokas Emmanouil, Conradi Lena, Weiss Christian, Sprenger Thilo, Middel Peter, Rau Tillman, Dellas Kathrin, Kitz Julia, Rödel Franz, Sauer Rolf, Rüschoff Josef, Beissbarth Tim, Arnold Dirk, Ghadimi B Michael, Rödel Claus, Liersch Torsten

Abstract excerpt

PURPOSE: We have previously shown that the addition of cetuximab to chemoradiation therapy failed to improve complete response rates (pCR) in rectal cancer. Here we report the long-term results of the cetuximab added to preoperative radiation therapy with capecitabine and oxaliplatin (CET-CAPOX-RT) phase 1/2 study that evaluated preoperative chemoradiation with cetuximab, capecitabine, and oxaliplatin in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Deoxycytidine

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Preoperative Care

Share to Rectal Neoplasms

Source

Identifiers

PMID: 24210078
DOI: 10.1016/j.ijrobp.2013.09.011

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.PMID 24210078Read ↗

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).Semantic proximity Read ↗

Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal CancerSemantic proximity Read ↗

Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: A case report and literature review.Semantic proximity Read ↗

Total Neoadjuvant Therapy and Organ Preservation in Locally Advanced Rectal Cancer: A State-of-the-Art Systematic Review and Critical AppraisalSemantic proximity Read ↗

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Semantic proximity Read ↗

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.Semantic proximity Read ↗

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).Semantic proximity Read ↗

KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.Semantic proximity Read ↗

Tumor Resectability and Pathologic Response After Neoadjuvant Long-Course Chemoradiotherapy for Locally Advanced Rectal Cancer in a Resource-Limited SettingSemantic proximity Read ↗

Genomic-adjusted radiation dose and outcomes in radiotherapy-treated locally advanced rectal cancer: a pooled multicohort analysis including the TIMING, OPRA, and CAO/ARO/AIO-94 prospective trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.